AVE 5883

Drug Profile

AVE 5883

Alternative Names: AVE-5883

Latest Information Update: 17 Mar 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aventis Pharmaceuticals
  • Class Antiasthmatics
  • Mechanism of Action Neurokinin 1 receptor antagonists; Neurokinin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 20 Jun 2006 Data presented at the 102nd International Conference of the American Thoracic Society (ATS-2006) have been added to the Obstructive Airways Disease therapeutic trials section
  • 29 Sep 2004 Phase-I/II clinical trials in Asthma in France (Inhalation)
  • 29 Sep 2004 Phase-I/II clinical trials in Asthma in Netherlands (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top